OBJECTIVE: To determine the relationship between joint variation in 2 dopaminergic genes and the likelihood of nonsmoking following treatment with bupropion sustained release (SR). DESIGN:Three hundred twenty-three participants in a bupropion SR smoking cessation effectiveness trial with 12-month follow-up were genotyped for variants of dopamine receptor gene DRD2 and dopamine transporter SLC6A3. MAIN OUTCOME MEASURES: Self-reported 7-day point prevalence of nonsmoking. RESULTS: Neither genotype alone was associated with 7-day point-prevalent nonsmoking at the 12-month follow-up. However, in the presence of the DRD2 A1 allele, SLC6A3 status was significantly associated with the likelihood of nonsmoking at the 12-month follow-up (individuals with DRD2 A1+ and SLC6A3 9- were more likely to be smoking). In the absence of the DRD2 A1 allele, the association between SLC6A3 status and nonsmoking was nonsignificant. CONCLUSION: Although these results are suggestive, a more compelling test is needed of the hypothesis that dopaminergic gene interaction underlies, in part, the likelihood of smoking following treatment with bupropion SR. Most likely this will come from larger studies involving prospective randomization to treatment based on genotype. Copyright (c) 2007 APA, all rights reserved.
RCT Entities:
OBJECTIVE: To determine the relationship between joint variation in 2 dopaminergic genes and the likelihood of nonsmoking following treatment with bupropion sustained release (SR). DESIGN: Three hundred twenty-three participants in a bupropion SR smoking cessation effectiveness trial with 12-month follow-up were genotyped for variants of dopamine receptor gene DRD2 and dopamine transporter SLC6A3. MAIN OUTCOME MEASURES: Self-reported 7-day point prevalence of nonsmoking. RESULTS: Neither genotype alone was associated with 7-day point-prevalent nonsmoking at the 12-month follow-up. However, in the presence of the DRD2 A1 allele, SLC6A3 status was significantly associated with the likelihood of nonsmoking at the 12-month follow-up (individuals with DRD2 A1+ and SLC6A3 9- were more likely to be smoking). In the absence of the DRD2 A1 allele, the association between SLC6A3 status and nonsmoking was nonsignificant. CONCLUSION: Although these results are suggestive, a more compelling test is needed of the hypothesis that dopaminergic gene interaction underlies, in part, the likelihood of smoking following treatment with bupropion SR. Most likely this will come from larger studies involving prospective randomization to treatment based on genotype. Copyright (c) 2007 APA, all rights reserved.
Authors: Riju Ray; James Loughead; Ze Wang; John Detre; Edward Yang; Ruben Gur; Caryn Lerman Journal: Behav Brain Res Date: 2008-06-05 Impact factor: 3.332
Authors: Kenneth Blum; Thomas J H Chen; John Bailey; Abdalla Bowirrat; John Femino; Amanda L C Chen; Thomas Simpatico; Siobhan Morse; John Giordano; Uma Damle; Mallory Kerner; Eric R Braverman; Frank Fornari; B William Downs; Cynthia Rector; Debmayla Barh; Marlene Oscar-Berman Journal: Mol Neurobiol Date: 2011-09-24 Impact factor: 5.590
Authors: Michele L Pergadia; Arpana Agrawal; Anu Loukola; Grant W Montgomery; Ulla Broms; Scott F Saccone; Jen C Wang; Alexandre A Todorov; Kauko Heikkilä; Dixie J Statham; Anjali K Henders; Megan J Campbell; John P Rice; Richard D Todd; Andrew C Heath; Alison M Goate; Leena Peltonen; Jaakko Kaprio; Nicholas G Martin; Pamela A F Madden Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2009-10-05 Impact factor: 3.568
Authors: Kenneth A Perkins; Caryn Lerman; Sarah Coddington; Christopher Jetton; Joshua L Karelitz; Annette Wilson; J Richard Jennings; Robert Ferrell; Andrew W Bergen; Neal L Benowitz Journal: Behav Pharmacol Date: 2008-09 Impact factor: 2.293
Authors: Christina N Lessov-Schlaggar; Michele L Pergadia; Taline V Khroyan; Gary E Swan Journal: Biochem Pharmacol Date: 2007-08-19 Impact factor: 5.858